adt + arpi + docetaxel

**adt + arpi + docetaxel** is a multi-agent combination therapy used in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). It comprises: - **Androgen Deprivation Therapy (ADT)**, which suppresses androgen production or blocks androgen receptors. - **Androgen Receptor Pathway Inhibitor (ARPi)**, which inhibits signaling via the androgen receptor (agents include abiraterone, enzalutamide, apalutamide, darolutamide). - **Docetaxel**, a cytotoxic chemotherapy agent that inhibits microtubule depolymerization. This regimen targets androgen signaling crucial for prostate cancer cell survival and proliferation, while docetaxel prevents cell division. The combination—sometimes called “triplet therapy”—has been shown in randomized controlled trials (PEACE-1, ARASENS, ENZAMET, TITAN, ARCHES) to improve overall survival and disease-free survival in patients with high-volume or de novo mHSPC compared to doublet regimens[1][3][2][5].

Other names

triplet therapy